Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
20,788,527
-
Number of holders
-
249
-
Total 13F shares, excl. options
-
174,896,826
-
Shares change
-
-1,986,724
-
Total reported value, excl. options
-
$4,050,261,692
-
Value change
-
-$44,584,638
-
Put/Call ratio
-
74%
-
Number of buys
-
112
-
Number of sells
-
-114
-
Price
-
$23.16
Significant Holders of Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NKTR) as of Q2 2020
295 filings reported holding NKTR - Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q2 2020.
Nektar Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NKTR) has 249 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 174,896,826 shares
.
Largest 10 shareholders include Invesco Ltd. (33,180,644 shares), PRIMECAP MANAGEMENT CO/CA/ (19,406,599 shares), FMR LLC (19,181,217 shares), BlackRock Inc. (18,683,127 shares), VANGUARD GROUP INC (16,500,862 shares), WELLINGTON MANAGEMENT GROUP LLP (15,151,481 shares), MAVERICK CAPITAL LTD (5,186,637 shares), STATE STREET CORP (4,464,647 shares), Bellevue Group AG (3,535,013 shares), and FIRST TRUST ADVISORS LP (3,399,045 shares).
This table shows the top 249 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.